Back to Search
JAIRIN DELA CRUZ, M.D.,BCBA
M.D.,BCBA
Behavior Analyst
NPI: 1447611207Individual
Specialties, Licenses & Credentials
Behavior AnalystPrimary
Behavior Analyst
Code: 103K00000X
1-16-21342(CA)
Research & Publications (20)
Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
PMID 15908002·Mol Immunol·2006
7-preclinical
Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
PMID 15967544·Vaccine·2005
7-preclinical
Antibody-cytokine fusion proteins: innovative weapons in the war against cancer.
PMID 15672942·Clin Exp Med·2004
6-review
Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice.
PMID 12615426·Vaccine·2003
7-preclinical
Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
PMID 11046042·J Immunol·2000
7-preclinical
Effects of the MEK inhibitor, SL-327, on rewarding, motor- and cellular-activating effects of D-amphetamine and SKF-82958, and their augmentation by food restriction in rat.
PMID 18766328·Psychopharmacology (Berl)·2009
7-preclinical
Isomeric identification by laser control mass spectrometry.
PMID 17173337·J Mass Spectrom·2007
8-other
Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.
PMID 16479517·J Infect Dis·2006
2-rct
Inositol phosphate metabolomics: merging genetic perturbation with modernized radiolabeling methods.
PMID 16829132·Methods·2006
6-review
Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma.
PMID 16380835·Invest New Drugs·2006
3-trial
Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
PMID 16125282·Vaccine·2006
7-preclinical
Quantitative mass spectrometric identification of isomers applying coherent laser control.
PMID 16834240·J Phys Chem A·2005
8-other
A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells.
PMID 15784746·Proc Natl Acad Sci U S A·2005
7-preclinical
Alteration of lithium pharmacology through manipulation of phosphoadenosine phosphate metabolism.
PMID 15583009·J Biol Chem·2005
8-other
Multiphoton Intrapulse Interference 8. Coherent control through scattering tissue.
PMID 19483957·Opt Express·2004
8-other
Use of coherent control methods through scattering biological tissue to achieve functional imaging.
PMID 15569924·Proc Natl Acad Sci U S A·2004
7-preclinical
Selective two-photon microscopy with shaped femtosecond pulses.
PMID 19466048·Opt Express·2003
8-other
An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.
PMID 12149472·Proc Natl Acad Sci U S A·2002
7-preclinical
CFC1 mutations in patients with transposition of the great arteries and double-outlet right ventricle.
PMID 11799476·Am J Hum Genet·2002
8-other
Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3).
PMID 11576465·J Interferon Cytokine Res·2001
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2332 PENNSYLVANIA AVE
FAIRFIELD, CA 94533 - Phone
- (707) 656-8522
Quick Facts
- NPI
- 1447611207
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile